Miguel
Fernández de Sanmamed Gutiérrez
Consultor Médico
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublications in collaboration with researchers from University of Texas MD Anderson Cancer Center (1)
2019
-
The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer
Journal of Thoracic Oncology, Vol. 14, Núm. 6, pp. 1046-1060